multivalent immunogenic composition, formulation, vial, pre-filled vaccine delivery device, kit, and

专利摘要:
multivalent immunogenic composition, formulation, vial, pre-filled vaccine delivery device, kit, and container the present invention relates to the immunogenic composition comprising a plurality of capsular polysaccharides of streptococcus pneumoniae from serotypes 1, 3, 4, 5, 6a , 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f conjugated to a carrier protein and additionally comprising at least one preservative, preferably 2-phenoxyethanol (2-pe). the preservative-containing immunogenic compositions of the invention provide resistance to one or more microorganisms and are useful for the production of multiple-dose vaccine formulations with advantageous properties with respect to the long-term stability of the different antigenic determinants in the immunogenic composition of choice. related compositions and methods are also presented for measuring the effectiveness of one or more condoms in a vaccine formulation.
公开号:BR112012030950B1
申请号:R112012030950
申请日:2011-05-25
公开日:2020-02-04
发明作者:Rashidbaigi Abbas；Khandke Lakshmi
申请人:Wyeth Llc；
IPC主号:

专利说明:

Invention Patent Descriptive Report for MULTIVALENT IMMUNOGENIC COMPOSITION, FORMULATION, BOTTLE, FILLED VACCINE DISTRIBUTION DEVICE, KIT, AND CONTAINER.
Background of the Invention [001] The present invention relates to pneumococcal disease caused by the bacterium Streptococcus pneumoniae (also known as pneumococcus) is one of the most important bacterial pathogens in the world. The cost of the disease is high in developing countries for children under five years of age where the vaccine is not available. Pneumococcal disease is a complex group of diseases and includes invasive infections, such as bacteremia / sepsis, meningitis, pneumonia and otitis media, which affect both children and adults. Prevenar 13 (also known as Prevenar 13 and referred to here as Prev (e) nar 13) is a polysaccharide formulation of thirteen pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F)) that are individually conjugated to CRM197 (Cross Reactivity Material of a mutant strain of Corynebacterim diphtheriae). Prev (e) nar 13 is recommended for active immunization of infants and young children to provide the broadest serotype coverage of any pneumococcal conjugate vaccine. Notably, serotype 19A in Prev (e) nar 13 is prevalent in many regions of the world and is often associated with antibiotic resistance. See, for example, WO2006 / 110381; WO2008 / 079653;
WO2008 / 079732; WO2008 / 143709 and references cited therein.
[002] Thimerosal (also known as Tiomersal; mertiolate) is a condom containing ethylmercury that has, since the early 1930s, been added to many injectable multi-dose formulations and topical solutions to protect them from potential contamination during exposure and when administered to multiple su
Petition 870190058765, of 6/25/2019, p. 3/64
2/46 ways. Thimerosal continues to be administered, as part of mandatory immunizations and in other pharmaceutical products in the United States and the rest of the world. It is claimed to be an effective preservative to eliminate potential contaminating bacteria during multiple use of products in the field, with minimal interaction with the antigenic structure and properties of vaccines. Due to growing controversies regarding potential safety issues and adverse effects of ethylmercury on the brain development of babies and young people, certain agencies have begun to recommend that alternative condoms be identified, with a minor or negligible safety risk. In 1999, a review by the North American Food and Drug Administration ordered by the North American Congress found that some babies could receive more mercury from vaccines than was considered acceptable under certain national guidelines. The American Academy of Pediatrics (AAP) and the North American Public Health Service (USPHS) issued a joint statement regarding thimerosal in vaccine, and then the AAP released an interim report to doctors recommending the removal of thimerosal from vaccines as soon as possible, while maintaining efforts to ensure that high levels of vaccination continue to be implemented worldwide, without affecting safety.
[003] The need to add condoms to vaccines can be reduced or eliminated by preparing and using only single dose vaccine formulations. However, the use of single-dose condom-free formulations raises the global costs of vaccination and jeopardizes the effectiveness of immunization programs in developing countries. In addition, complete removal of condoms from multiple dose bottles is not seen as a preferred option, particularly in countries with limited cold storage and standards
Petition 870190058765, of 6/25/2019, p. 4/64
3/46 health care sub-optimals (Drain et al., Bull World Health Organ 81 (10): 726 - 731 (2003). In 1928, twelve of 21 children inoculated with the vaccine for contaminated diphtheria died of multiple staphylococcal abscesses and toxemia (Wilson, The Hazards of Immunization, Athlone Press, London. pp. 75 - 78 (1967). Thus, although multi-dose vials appear to be the most appropriate for the production of less expensive vaccines, it is desirable to formulate multi-dose vaccines. with at least one condom to protect subjects against microorganisms inadvertently introduced into the vaccine during multiple uses or after one or more non-sterile events.The effectiveness of condoms in resisting bacterial contamination and by other microorganisms must be counterbalanced, however , with the effect that a particular condom has on immunogenicity, as well as on the long-term stability of each different antigenic determinant in a cell. immunogenic choice of choice. The compatibility of Prev (e) nar 13 formulations with condoms had not been previously treated. It would be desirable to have an optimized formulation comprising at least one preservative that would protect and / or stabilize antigenic determinants of the pneumococcal antigenic serotypes present in Prev (e) nar 13. Summary of the Invention [004] In a first aspect, the present invention features an immunogenic composition multivalent comprising a plurality of capsular polysaccharides from serotypes of Streptococcus pneumoniae and 2-phenoxyethanol (2-PE). In certain embodiments, the capsular polysaccharides are from one or more serotypes of Streptococcus pneumoniae selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. In certain embodiments, the capsular polysaccharides are from seven or more of the Streptococcus pneumoniae serotypes selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. In cer
Petition 870190058765, of 6/25/2019, p. 5/64
4/46 In these modalities, the capsular polysaccharides are from each of the Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
[005] In certain embodiments of the invention, the composition comprises 2-PE at a concentration between 7 mg / ml and 15 mg / ml, of about 10 mg / ml, of at least 7 mg / ml, of at least 10 mg / ml or of at least 15mg / mL.
[006] Immunogenic compositions of the invention may also, in certain embodiments, comprise one or more of an adjuvant, a buffer, a cryoprotectant, a salt, a divalent cation, a non-ionic detergent and an inhibitor of free radical oxidation. In certain embodiments, the adjuvant is aluminum phosphate.
[007] A preferred multivalent immunogenic composition of the invention is a pneumococcal capsular polysaccharide formulation of serotypes 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, individually conjugated to CRM197, wherein the multivalent immunogenic composition is formulated in a sterile liquid to comprise: about 4.4 pg / ml of each polysaccharide, except for 6B to about 8.8 pg / ml; about 58 pg / ml of CRM197 vehicle protein; about 0.25 mg / mL of elemental aluminum in the form of aluminum phosphate; about 0.85% sodium chloride; about 0.02% polysorbate 80; about 5 mM sodium succinate buffer at a pH of 5.8; and about 10 mg / ml of 2-phenoxyethanol.
[008] In certain embodiments of the invention, the antigenicity of the immunogenic composition is stable for at least 1 year, 1.5 years, 2 years or 2.5 years at a temperature of 2-8 ° C, 20-2 5 ° C or 37 ° C.
[009] In certain embodiments of the invention, after inoculation of the immunogenic composition with one or more microorganisms, the concentration of said microorganisms is reduced with time. In certain modalities, after inoculation with one or more bacte strains
Petition 870190058765, of 6/25/2019, p. 6/64
5/46 rianas, the composition shows a reduction of at least 1.0 log of the initial count of microorganisms in 24 hours, a reduction of at least 3.0 * (ok) log in 7 days in relation to the previously measured value and an increase of a maximum of 0.5 * log after 28 days, from the previously measured value. In certain embodiments, after inoculation with one or more bacterial strains, the composition exhibits a reduction of at least 2.0 * log from the initial calculated count at 6 hours after inoculation, a reduction of at least 3.0 * log from the value previously measured in 24 hours and no recovery in 28 days. Strains of microorganisms include one or more strains selected from P. aeruginosa, S. aureus, E. coli and B. subtilis.
[0010] In certain embodiments, the immunogenic composition is inoculated multiple times. In certain embodiments, a second inoculation occurs within 6 hours after the initial inoculation, a third inoculation occurs within 24 hours after the initial inoculation, a third inoculation occurs within 7 days after the initial inoculation, and a fourth inoculation occurs within 14 days after the initial inoculation. initial inoculation.
[0011] In a second aspect, the present invention also features a vial containing a multivalent immunogenic composition of the invention. The vial may contain a single dose or more than one dose of the immunogenic composition. The invention also features a pre-filled vaccine delivery device comprising a multivalent immunogenic composition of the invention. In certain embodiments, the pre-filled vaccine delivery device is or comprises a syringe. Vaccine delivery devices of the invention may comprise a double or multiple chamber syringe or vials or combinations thereof. In certain embodiments, the pre-filled vaccine delivery device comprises a multivalent immunogenic composition formulated for intramuscular or subcutaneous injection.
Petition 870190058765, of 6/25/2019, p. 7/64
[0012] In a third aspect, the present invention also features a kit for the preparation of a multivalent immunogenic composition of the invention, wherein the kit comprises (i) a plurality of capsular polysaccharides in a lyophilized form of the composition, and (ii) aqueous material to reconstitute component (i) to provide the aqueous composition.
[0013] In a fourth aspect, the present invention features a multiple dose vaccine comprising four doses of a vaccine in a vial, each dose comprising from 4 to 20 mg / ml, preferably 10 mg / ml of 2-phenoxyethanol, in the dose is 0.5 ml of vaccine.
[0014] In a fifth aspect, the present invention also provides a method for measuring the effectiveness of a vaccine formulation comprising one or more preservative agents selected in the presence of some or all of the immunogenic and non-immunogenic components of the vaccine composition, in that the test comprises at least two steps of inoculating the test composition with a population of selected microorganisms and comparing the * log reduction of the inoculated microorganism (s) over time and under environmental conditions (for example, temperature) with a * log reduction in a control composition without the test condom (s).
Brief Description of the Drawings [0015] Figure 1 - Efficacy of Thimerosal as a vaccine preservative in various formulations.
[0016] Figure 2 - Efficacy and stability of 2-phenoxyethanol (2-PE) as a vaccine preservative in various formulations and at different concentrations.
[0017] Figure 3 - Time course of reduction of microorganism colony count in the Prev (e) nar 13 vaccine formulation
Petition 870190058765, of 6/25/2019, p. 8/64
7/46 without any condom at 20-25 ° C after a single challenge with microorganisms (expressed as change in mean logw compared to the time of challenge at t = 0, 6 hours, 24 hours, 7 days, 14 days and 28 days).
[0018] Figure 4 - Time course of reduction of microorganism colony count in the Prev (e) nar 13 vaccine formulation with 0.01% Thimerosal at 20-25 ° C after a single challenge with microorganisms (expressed as change in mean logw compared to the time of challenge at t = 0, 6 hours, 24 hours, 7 days, 14 days and 28 days).
[0019] Figure 5 - Time course of reduction of microorganism colony count in the vaccine formulation Prev (e) nar 13 with 0.02% Thimerosal at 20-25 ° C after a single challenge with microorganisms (expressed as change in mean logw compared to the time of challenge at t = 0, 6 hours, 24 hours, 7 days, 14 days and 28 days).
[0020] Figure 6 - Time course of reduction of microorganism colony count in saline with 0.02% Timerosal at 2025 ° C after a single challenge with microorganisms (expressed as change in log10 mean compared to challenge at t = 0, 6 hours, 24 hours, 7 days, 14 days and 28 days).
[0021] Figure 7 - Time course of reducing the microorganism colony count in the Prev (e) nar 13 vaccine formulation with 5 mg / 0.5 mL of 2-phenoxyethanol at 20-25 ° C after a single challenge with microorganisms (expressed as change in mean logw compared to the time of challenge at t = 0, 6 hours, 24 hours, 7 days, 14 days and 28 days).
[0022] Figure 8 - Time course of reduction of microorganism colony count in the vaccine formulation Prev (e) nar 13 without any preservative at (A) 22 - 24 ° C or at (B) 2 - 8 ° C after mu
Petition 870190058765, of 6/25/2019, p. 9/64
8/46 multiple challenges with microorganisms at t = 0, 6 hours, 24 hours, 7 days and 14 days (expressed as change in mean logw compared to the time of challenge at t = 0, 6 hours, 24 hours, 7 days, 14 days and 28 days).
[0023] Figure 9 - Time course of reduction of microorganism colony count in the vaccine formulation Prev (e) nar 13 with 0.01% of Thimerosal at (A) 22 - 24 ° C or at (B) 2 - 8 ° C, after multiple challenges with microorganisms at t = 0, 6 hours, 24 hours, 7 days and 14 days, (expressed as change in mean logw compared to the time of challenge at t = 0, 6 hours , 24 hours, 7 days, 14 days and 28 days).
[0024] Figure 10 - Time course of reduction of microorganism colony count in the vaccine formulation Prev (e) nar 13 with 0.02% of Thimerosal at (A) 22 - 24 ° C or at (B) 2 - 8 ° C after multiple challenges with microorganisms at t = 0, 6 hours, 24 hours, 7 days and 14 days (expressed as change in mean logw compared to the time of challenge at t = 0, 6 hours, 24 hours, 7 days, 14 days and 28 days).
[0025] Figure 11 - Time course of reduction of microorganism colony count in saline with 0.02% thimerosal at (A) 22 - 24 ° C or at (B) 2 - 8 ° C after multiple challenges with microorganisms at t = 0, 6 hours, 24 hours, 7 days and 14 days (expressed as change in log10 mean compared to the time of challenge at t = 0, 6 hours, 24 hours, 7 days, 14 days and 28 days ).
[0026] Figure 12 - Nonlinear regression analysis of S. aureus decay in several challenge studies.
[0027] Figure 13 - Comparison of 2-PE and Thimerosal as a preservative for vaccines against single or multiple challenges with microorganisms: success or failure according to EP 5.1.3 criterion B.
[0028] Figure 14 - Long-term stability of the antigenicity of
Petition 870190058765, of 6/25/2019, p. 10/64
9/46 preparations of Streptococcus pneumoniae polysaccharides of each serotype in Prev (e) nar 13 formulated with 5 mg of 2-PE.
[0029] Figure 15 - Long-term stability of 2-PE in the vaccine formulation Prev (e) nar 13.
Detailed Description of the Invention [0030] The percentage of concentration, as used in this application, is in weight for volume (w / v) or weight for weight (w / w).
[0031] Unless otherwise specified, dose refers to a 0.5 mL vaccine dose.
[0032] The term multiple doses refers to a composition comprising more than one dose of vaccine, which can be administered to one subject or to more than one subject at different stages of administration and over time.
[0033] The present invention features a multivalent immunogenic composition comprising a plurality of capsular polysaccharides of serotypes of Streptococcus pneumoniae (also known as pneumococci) and a preservative. This composition can also be called a vaccine and can be used to induce an immune response against pneumococci and to protect against infections in a subject, for example, a human subject, preferably a human child or baby.
[0034] A plurality of any Streptococcus pneumoniae capsular polysaccharides is suitable for the composition of the present invention. In certain embodiments of the invention, the multivalent immunogenic composition comprises capsular polysaccharides prepared with serotypes 4, 6B, 9V, 14, 18C, 19F and 23F of Streptococcus pneumoniae. In certain embodiments, capsular polysaccharides are prepared with serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and at least one additional serotype of Streptococcus pneumoniae. In certain embodiments, capsular polysaccharides are prepared in accordance with 870190058765, dated 06/25/2019, p. 11/64
10/46 with at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9 serotypes selected from serotypes 1,4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F of Streptococcus pneumoniae. In certain embodiments, capsular polysaccharides are prepared with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F of Streptococcus pneumoniae. Capsular polysaccharides of the invention are prepared with serotypes of Streptococcus pneumoniae using known techniques. See, for example, International Patent Applications WO2006 / 110381; WO2008 / 079653;
WO2008 / 079732 and WO2008 / 143709, each incorporated herein by reference.
[0035] In certain embodiments of the invention, capsular polysaccharides are conjugated to a carrier protein. These pneumococcal conjugates can be prepared separately. For example, in one embodiment, each pneumococcal polysaccharide serotype is grown in a soy-based medium. The individual polysaccharides are then purified by centrifugation, precipitation, ultrafiltration and column chromatography. The purified polysaccharides are chemically activated so that the saccharides are able to react with the selected carrier protein to form pneumococcal conjugates.
[0036] Once activated, each capsular polysaccharide is separately conjugated to a carrier protein to form a glycoconjugate. In certain embodiments, each different capsular polysaccharide is conjugated to the same carrier protein. In these modalities, the conjugation can be carried out, for example, by reducing amination. [0037] The chemical activation of the polysaccharides and the subsequent conjugation to the vehicle protein are achieved by conventional means. See, for example, US Patents No. 4,673,574 and 4,902,506, incorporated herein by reference.
Petition 870190058765, of 6/25/2019, p. 12/64
11/46 [0038] Vehicle proteins are preferably proteins that are non-toxic and non-reactogenic and obtainable in sufficient quantity and purity. Vehicle proteins must be amenable to standard conjugation procedures. In certain embodiments of the present invention, CRM197 is used as the vehicle protein.
[0039] CRM197 (Pfizer, Sanford, NC) is a non-toxic (ie toxoid) variant of diphtheria toxin isolated from Corynebacterium diphtheria strain C7 (CRM197) cultures grown in casamino acids and a medium based on yeast extract. CRM197 is purified by ultrafiltration, precipitation with ammonium sulfate and ion exchange chromatography. Alternatively, CRM197 is prepared recombinantly, in accordance with, for example, U.S. Patent No. 5,614,382, which is incorporated herein by reference. Other diphtheria toxoidethoxy are also suitable for use as carrier proteins.
[0040] Other suitable carrier proteins include inactivated bacterial toxins, such as tetanus toxoid, pertussis toxoid, cholera toxoid (for example, as described in International Patent Application WO2004 / 083251), E. coli LT, E. coli ST and exotoxin A from Pseudomonas aeruginosa. Bacterial outer membrane proteins, such as outer membrane complex c (OMPC), porins, transferrin-binding proteins, pneumolysin, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA), Group A streptococcal peptidase C5a or Group B or Haemophilus influenzae protein D, can also be used. Other proteins, such as ovalbumin, Californian keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or the purified tuberculin protein derivative (PPD), can also be used as carrier proteins.
[0041] After conjugation of the capsular polysaccharide to the vehicle protein, the polysaccharide-protein conjugates are purified
Petition 870190058765, of 6/25/2019, p. 13/64
12/46 (that is, enriched with respect to the amount of polysaccharide-protein conjugate) by various techniques. These techniques include concentration / diafiltration, precipitation / elution, column chromatography and depth filtration.
[0042] As discussed in more detail below, the immunogenic compositions of the present invention comprise at least one condom usable for the production of multiple dose vaccine formulations with advantageous properties with respect to the long-term stability of one or more antigenic determinants of the conjugates. of multivalent pneumococcal-protein capsular polysaccharide and which advantageously protects the compositions against contamination by conferring resistance to one or more microorganisms before administration to a needy subject.
[0043] The additional formulation of the immunogenic composition containing the preservative of the present invention can be carried out using methods recognized in the art. For example, the thirteen individual pneumococcal conjugates can be formulated with a physiologically acceptable vehicle to prepare the composition. Examples of such vehicles include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and dextrose solutions, as described in greater detail below.
[0044] The immunogenic compositions of the invention comprise one or more preservatives, in addition to a plurality of pneumococcal-protein capsular polysaccharide conjugates. The FDA requires that biological products in multi-dose (multi-dose) bottles contain a condom, with only a few exceptions. Vaccine products containing condoms include vaccines containing benzethonium chloride (anthrax), 2-phenoxyethanol (DTaP, HepA, Lyme, Polio (parenteral)), phenol (Pneumo, Typhoid (parenteral), Vaccinia) and thimerosal (DTaP, DT, Td , HepB, Hib, Influenza, JE, Mening, Pneumo, Rabies).
Petition 870190058765, of 6/25/2019, p. 14/64
13/46
Condoms approved for use in injectable drugs include, for example, chlorobutanol, m-cresol, methylparaben, propylparaben, 2-phenoxyethanol, benzethonium chloride, benzalkonium chloride, benzoic acid, benzyl alcohol, phenol, thimerosal and phenylmercuric nitrate.
[0045] Having tested several potentially suitable formulations comprising a preservative for greater efficacy and stability of the immunogenic compositions of Prev (e) nar 13, the invention set forth here presents those pneumococcal immunogenic compositions comprising 2-phenoxyethanol (2-PE) at a concentration of about 2.5 - 10 mg / dose (0.5 - 2%). In certain embodiments, the concentration of 2-PE is about 3.5 - 7.5 mg / dose (0.7 - 1.5%). In certain embodiments, the concentration of 2-PE is about 5 mg / dose (1%). In certain embodiments, the concentration of 2-PE is at least 3.5 mg / dose (0.7%), at least 4.0 mg / dose (0.8%), and at least 4.5 mg / dose (0.9%), at least 5.0 mg / dose (1%), at least 5.5 mg / dose (1.1%), at least 6.0 mg / dose (1 , 2%), at least 6.5 mg / dose (1.3%), at least 7.0 mg / dose, at least 7.5 mg / dose (1.5%), at least 8.0 mg / dose (1.6%), at least 9.0 mg / dose (1.8%) or at least 10 mg / dose (2%).
[0046] In certain embodiments of the invention, pneumococcal immunogenic compositions contain one or more additional preservatives including, but not limited to, Thimerosal and formalin.
[0047] In certain embodiments, the immunogenic composition may comprise one or more adjuvants. As defined herein, an adjuvant is a substance that serves to increase the immunogenicity of an immunogenic composition of this invention. Thus, adjuvants are often given to enhance the immune response and are well known to those skilled in the art. Suitable adjuvants to increase the effectiveness of the composition include, but are not limited to:
Petition 870190058765, of 6/25/2019, p. 15/64
14/46 [0048] (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate and others;
[0049] (2) oil in water emulsion formulations (with or without other specific immunostimulating agents, such as muramyl peptides (defined below) or bacterial cell wall components), such as, for example, [0050] (a) MF59 (PCT Application WO 90/14837), containing 5% squalene, 0.5% Tween 80 and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below, although not required)), formulated in submicron particles using a microfluidizer, such as the Model 110Y microfluidizer (Microfluidics, Newton, MA), [0051] (b) SAF, containing 10% squalene, 0.4% Tween 80,
5% pluronic blocked polymer L121 and thr-MDP (see below), microfluidized in a submicrometric emulsion or swirled to generate an emulsion with larger particle size, and [0052] (c) Ribi adjuvant system (RAS), (Corixa, Hamilton, MT) containing 2% squalene, 0.2% Tween 80 and one or more bacterial cell wall components of the group consisting of monophosphoryl lipid 3-O-deacylated A (MPL) described in U.S. Patent No. 4,912. 094 (Corixa), trehalose dimicolate (TDM) and cell wall skeleton (CWS), preferably MPL + CWS (Detox);
[0053] (d) Polysorbate 80 (Tween 80);
[0054] (3) saponin adjuvants, such as Quil A or STIMULON
QS-21 (Antigenics, Framingham, MA) (U.S. Patent No. 5,057,540), can be used or the particles generated from them, as ISCOMs (immunostimulating complexes);
[0055] (4) bacterial lipopolysaccharides, synthetic lipid A analogues, such as aminoalkyl glucosamine phosphate compounds (AGP), or their derivatives or analogs, which are available from Cori
Petition 870190058765, of 6/25/2019, p. 16/64
15/46 xa, and which are described in U.S. Patent No. 6,113,918; one of these AGP is 2 - [(R) -3-Tetradecanoyloxytetradecanoylamino] ethyl -glucopyranoside, which is also known as 529 (formerly known as RC529), which is formulated as an aqueous form or as a stable emulsion, synthetic polynucleotides, as oligonucleotides containing CpG motif (s) (U.S. Patent No. 6,207,646 );
[0056] (5) cytokines, such as interleukins (e.g., IL-1, IL-2, IL4, IL-5, IL-6, IL-7, IL-12, IL-15, IL-18 and others) , interferons (eg, gamma interferon), granulocyte macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), co-stimulating molecules B7-1 and B7 -2 and others;
[0057] (6) detoxified mutants of a ribosylation toxin from
Bacterial ADP, such as cholera toxin (CT) of the wild type or in mutant form, for example, in which the glutamic acid at the position of amino acid 29 is replaced by another amino acid, preferably a histidine, according to the international patent application published number WO 00/18434 (see also WO 02/098368 and WO 02/098369), a pertussis toxin (PT) or an E. coli toxin (LT) thermolabile toxin, particularly LT-K63, LT-R72, CT -S109, PT-K9 / G129 (see, for example, WO 93/13302 and WO 92/19265); and [0058] (7) other substances that act as immunostimulating agents to increase the effectiveness of the composition, such as calcium salt, iron, zinc, acylated tyrosine suspension, acylated sugar, derivatized sugars / saccharides, polyphosphazenes, biodegradable microspheres, monophosphoryl lipid A (MPL), derivatives of lipid A (for example, of reduced toxicity), MPL 3-O-deacylated, kil A, Saponin, QS21, tocol, Freund's Incomplete Adjuvant (Difco Laboratories, De
Petition 870190058765, of 6/25/2019, p. 17/64
16/46 troit, MI), Merck 65 Adjuvant (Merck and Company, Inc., Rahway, NJ), AS-2 (Smith-Kline Beecham, Philadelphia, PA), CpG oligonucleotides (preferably unmethylated), bioadhesives and mucoadhesives , microparticles, liposomes, polyoxyethylene ether formulations, polyoxyethylene ester formulations and muramyl peptides or imidazoquinolone compounds. Muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetylnormuramyl-L-alanine-2- (1'-2 'dipalmitoil-sn- glycero-3-hydroxyphosphoryloxy) ethylamine (MTP-PE), and others.
[0059] In certain embodiments, the adjuvant composition is one that favors the induction of TH1 type cytokines (for example IFN-γ, TNFa, IL-2 and IL-12) to a greater extent than TH2 type cytokines, which can favor the induction of cell-mediated immune responses to an administered antigen. Particular adjuvant systems that promote a predominantly TH1 response include, but are not limited to, lipid A derivatives, such as Monophosphoryl lipid A (MPL) or its derivatives, for example, MPL 3-de-O-acylate (3D-MPL), a combination of MPL and / or 3D-MPL and an aluminum salt and / or a saponin derivative (for example, QS21 in combination with 3DMPL as set out in WO 94/00153, or QS21 and cholesterol as set out in WO 96/33739 ), triterpenoids and oil-in-water emulsions, as one comprising tocopherol (as set out in WO 95/17210).
[0060] An adjuvant can optionally be adsorbed or combined with one or more of the immunogenic components of the preserved vaccine formulation of the invention. As used herein, the term adsorbed antigen refers to a mixture in which more than 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of an antigen is adsorbed on the adjuvant. In certain embodiments, the adjuvant is aluminum phosphate (Al +) or adsorbed aluminum hydroxyphosphate. Typically, the
Petition 870190058765, of 6/25/2019, p. 18/64
17/46 total aluminum is 200 - 1,000 pg, 300 - 900 pg, 400 - 800 pg, 500 700 pg or about 630 pg of Al + per 0.5 ml dose, which can be totally aluminum hydroxide or totally phosphate aluminum. Alternatively, the Al + content can be a mixture of aluminum hydroxide and aluminum phosphate in various ratios, for example, 1: 8 8: 1, 1: 4 - 4: 1, 3: 8 - 8: 3, 1 : 2 - 2: 1 or 1: 1 of aluminum phosphate: aluminum hydroxide. Although most of the aluminum is supplied by pre-adsorbed antigens before mixing to form a combination vaccine, part of the aluminum can be added in free form during the formulation of the combination vaccine of the invention, for example, before the adjustment step pH described here. Typically, the free aluminum content per 0.5 ml dose can be 0 - 300 pg, 50 - 250 pg, 75 - 200 pg, 100 - 150 pg or about 120 pg of Al3 +. The free Al3 + can be totally Al (OH) 3 or totally AlPO4, or a mixture of Al (OH) 3 and A1PO4 for several reasons.
[0061] The antigenic components of the vaccine can be pre-adsorbed into an aluminum salt individually before mixing. In another embodiment, a mixture of antigens can be pre-adsorbed before mixing with additional adjuvants. Alternatively, certain components of the vaccines of the invention can be formulated, but not intentionally adsorbed on the adjuvant.
[0062] Formulations of the invention may also comprise one or more of a buffer, a salt, a divalent cation, a nonionic detergent, a cryoprotectant, like a sugar, and an antioxidant, like a free radical scavenger or chelating agent, any of its multiple combinations. The choice of any component, for example, a chelator, can determine whether or not another component (for example, a remover) is desirable. The final composition formulated for administration must be sterile and / or free of pyrogens. Those skilled in the art can empirically determine which combination
Petition 870190058765, of 6/25/2019, p. 19/64
18/46 nations of these and other components will be optimal for inclusion in vaccine compositions containing preservatives of the invention, depending on several factors, such as the particular conditions of storage and administration required.
[0063] In certain embodiments, a formulation of the invention that is compatible with parenteral administration comprises one or more physiologically acceptable buffers selected from, but not limited to, Tris (trimethamine), phosphate, acetate, borate, citrate, glycine, histidine and succinate . In certain embodiments, the formulation is buffered within a pH range of about 6.0 to about 9.0, preferably from about 6.4 to about 7.4.
[0064] In certain embodiments, it may be desirable to adjust the pH of an immunogenic composition or formulation of the invention. The pH of a formulation of the invention can be adjusted using standard techniques. The formulation pH can be adjusted to be between 3.0 and 8.0. In certain embodiments, the pH of the formulation can be, or can be adjusted to be, between 3.0 and 6.0, 4.0 and 6.0 or 5.0 and 8.0. In other embodiments, the pH of the formulation can be, or can be adjusted to be, about 3.0, about 3.5, about 4.0, about 4.5, about 5.0, about of 5.5, about 5.8, about 6.0, about 6.5, about 7.0, about 7.5, or about 8.0. In certain embodiments, the pH can be, or can be adjusted to be, in a range of 4.5 to 7.5, or from 4.5 to 6.5, from 5.0 to 5.4, from 5, 4 to 5.5, 5.5 to 5.6, 5.6 to 5.7, 5.7 to 5.8, 5.8 to 5.9, 5.9 to 6.0 , from 6.0 to 6.1, from 6.1 to 6.2, from 6.2 to 6.3, from 6.3 to 6.5, from 6.5 to 7.0, from 7.0 to 7.5 or 7.5 to 8.0. In a specific embodiment, the pH of the formulation is about 5.8.
[0065] In certain embodiments, a formulation of the invention that is compatible with parenteral administration comprises one or more divalent cations, including, but not limited to, MgCl2, CaCl2 and
Petition 870190058765, of 6/25/2019, p. 20/64
19/46
MnCl2, at a concentration ranging from about 0.1 mM to about 10 mM, with up to about 5 mM being preferred.
[0066] In certain embodiments, a formulation of the invention that is compatible with parenteral administration comprises one or more salts, including, but not limited to, sodium chloride, potassium chloride, sodium sulfate and potassium sulfate, present at a strength ion that is physiologically acceptable to the subject during parenteral administration and included at a final concentration that produces an ionic strength or osmolarity selected in the final formulation. The ionic strength or final osmolality of the formulation will be determined by multiple components (for example, ions of the buffering compound (s) and other non-buffering salts). A preferred salt, NaCl, is present in a range of up to about 250 mM, with the concentrations of the salt being selected to complement other components (for example, sugars), so that the final total osmolarity of the formulation is compatible with administration parenteral (for example, intramuscular or subcutaneous injection) and promotes the long-term stability of the immunogenic components of the vaccine formulation at various temperature ranges. Salt-free formulations tolerate increased ranges of one or more selected cryoprotectants to maintain the desired final osmolarity levels.
[0067] In certain embodiments, a formulation of the invention that is compatible with parenteral administration comprises one or more cryoprotectants selected from, but not limited to, disaccharides (eg, lactose, maltose, sucrose or trehalose) and polyhydroxy hydrocarbons (eg. dulcitol, glycerol, mannitol and sorbitol).
[0068] In certain embodiments, the osmolarity of the formulation is in a range of about 200 mOs / L to about 800 mOs / L, with a preferred range of about 250 mOs / L to about 500 mOs / L, or in
Petition 870190058765, of 6/25/2019, p. 21/64
20/46 about 300 mOs / L to about 400 mOs / L. A salt-free formulation can contain, for example, from about 5% to about 25% sucrose and, preferably, from about 7% to about 15%, or from about 10% to about 12% of sucrose. Alternatively, a salt-free formulation can contain, for example, from about 3% to about 12% sorbitol and, preferably, from about 4% to 7%, or from about 5% to about 6% sorbitol. If a salt such as sodium chloride is added, then the effective range of sucrose or sorbitol is relatively reduced. These and other considerations of osmolality and osmolarity are within the reach of those skilled in the art.
[0069] In certain embodiments, a formulation of the invention that is compatible with parenteral administration comprises one or more inhibitors of oxidation of free radicals and / or chelating agents. Various free radical scavengers and chelators are known in the art and apply to the formulations and methods of use described herein. Examples include, but are not limited to, ethanol, EDTA, an EDTA / ethanol combination, triethanolamine, mannitol, histidine, glycerol, sodium citrate, inositol hexaphosphate, tripolyphosphate, ascorbic acid / ascorbate, succinic acid / succinate, mallic acid / maleate, desferal, EDDHA and DTPA, and various combinations of two or more of the above. In certain embodiments, at least one non-reducing free radical scavenger can be added to a concentration that effectively increases the formulation's long-term stability. One or more inhibitors of oxidation of free radicals / chelators can also be added in various combinations, such as a remover and a divalent cation. The choice of the chelator will determine whether or not it is necessary to add a remover.
[0070] In certain embodiments, a formulation of the invention that is compatible with parenteral administration comprises one or more nonionic surfactants, including, but not limited to, esters
Petition 870190058765, of 6/25/2019, p. 22/64
21/46 polyoxyethylene sorbitan fatty acid, Polysorbate-80 (Tween 80), Polysorbate-60 (Tween 60), Polysorbate-40 (Tween 40) and Polysorbate-20 (Tween 20), alkyl polyoxyethylene ethers, including, but not limited to a, Brij 58, Brij 35, as well as others like Triton X100; Triton X-114, NP40, Span 85 and the Pluronic series of non-ionic surfactants (eg Pluronic 121), with the preferred components being Polysorbate-80 at a concentration of about 0.001% to about 2% (with up to about 0.25% being preferred) or Polysorbate-40 at a concentration of about 0.001% to 1% (with up to about 0.5% being preferred).
[0071] In certain embodiments, a formulation of the invention comprises one or more additional stabilizing agents suitable for parenteral administration, for example, a reducing agent comprising at least one thiol group (-SH) (for example, cysteine, Nacetyl cysteine, reduced glutathione , sodium thioglycolate, thiosulfate, monothioglycerol or mixtures thereof). Alternatively or optionally, vaccine formulations containing preservatives of the invention can be further stabilized by removing oxygen from storage containers, protecting the formulation from light (for example, using amber glass containers).
[0072] Vaccine formulations containing preservatives of the invention may comprise one or more pharmaceutically acceptable vehicles or excipients, which include any excipient that does not itself induce an immune response. Suitable excipients include, but are not limited to, macromolecules, such as proteins, saccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose (Paoletti et al, 2001, Vaccine, 19: 2118), trehalose, lactose and aggregates of lipids (like oil droplets or liposomes). Such vehicles are well known to those skilled in the art. Pharmaceutically acceptable excipients are
Petition 870190058765, of 6/25/2019, p. 23/64
22/46 discussed, for example in Gennaro, 2000, Remington: The Science and Practice of Pharmacy, 20th edition, ISBN: 0683306472.
[0073] The compositions of the invention can be lyophilized or in aqueous form, that is, solutions or suspensions. Liquid formulations can advantageously be administered directly from their packaged form and are, therefore, ideal for injection, without the need for reconstitution in aqueous medium, as is otherwise required for lyophilized compositions of the invention.
[0074] In particular embodiments of the present invention, the vaccine is a multivalent immunogenic composition comprising one or more pneumococcal capsular polysaccharides selected from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, individually combined with CRM197. The vaccine is formulated to comprise: from 1 to 5 pg, preferably about 4.4 pg / ml of each polysaccharide, but preferably about 8.8 pg / ml of 6B; from 20 to 100 pg / ml, preferably about 58 pg / ml of CRM197 vehicle protein; from 0.02 to 2 mg / ml, preferably 0.25 mg / ml of elemental aluminum in the form of aluminum phosphate; from 0.5 to 1.25%, preferably about 0.85% sodium chloride; from 0.002 to 0.2%, preferably about 0.02% of polysorbate 80; from 1 to 10 mM, preferably about 5 mM of sodium succinate buffer at a pH of 4 to 7, preferably at a pH of 5.8; and from 4 to 20 mg / ml, preferably about 10 mg / ml of 2-phenoxyethanol.
[0075] In certain preferred embodiments of the present invention, the vaccine is a multivalent immunogenic composition comprising pneumococcal capsular polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, individually combined with CRM197. The vaccine is formulated to comprise: about 4.4 pg / ml of each saccharide, except for 6B to about 8.8 pg / ml; about 58 pg / ml of CRM197 vehicle protein; about 0.25 mg / mL of
Petition 870190058765, of 6/25/2019, p. 24/64
23/46 elemental aluminum in the form of aluminum phosphate; about 0.85% sodium chloride; about 0.02% polysorbate 80; about 5 mM sodium succinate buffer at a pH of 5.8; and about 10 mg / ml of 2-phenoxyethanol.
[0076] The amount of many of the materials that the composition of the invention can comprise can be expressed as weight / dose, weight / volume or% concentration (such as weight / volume or weight / weight). All of these values can be converted to each other. For conversions to and from a weight / dose unit, a dose volume is specified. For example, given a dose of 0.5 ml, 5.0 mg / dose of 2-PE is equivalent to a concentration of 10 mg / ml or 1.0% (g / 100mL).
[0077] The vaccine formulation can also be expressed as a polysaccharide: 2-PE ratio. For example, a dose of 0.5 ml of the preferred formulation of 4.4 pg / ml of each saccharide, except for 6B to 8.8 pg / ml, and 10 mg / ml of 2-PE will have 30.8 pg of polysaccharide (2.2 pg x 12 serotypes + 4.4 pg for serotype 6B) and 5,000 pg of 2-PE. Consequently, the weight ratio of polysaccharide: 2-PE is 30.8: 5,000.
[0078] In certain embodiments of the invention, the polysaccharide: 2-PE weight ratio of the vaccine is 5: 5,000 to 100: 5,000. In a preferred embodiment of the invention, said weight ratio of polysaccharide: 2-PE is about 30.8: 5,000.
Distribution of Vaccine Formulations [0079] There are also methods of using the pharmaceutical compositions and formulations presented comprising at least one condom to induce an immune response against pneumococci in a mammalian subject, such as a human subject, preferably in a child or baby, and thereby protect against infections. The vaccine formulations of the present invention can be used to protect a human subject susceptible to pneumococcal infection
Petition 870190058765, of 6/25/2019, p. 25/64
24/46 by administration of the vaccine through a systemic or mucosal route. Such administrations may include, for example, parenteral administration or mucous administration to the oral / alimentary, respiratory or genitourinary tracts.
[0080] Direct delivery of vaccine preparations of the present invention to a subject can be carried out by parenteral administration (intramuscular, intraperitoneal, intradermal, subcutaneous, intravenous or to the interstitial space of a tissue); or by rectal, oral, vaginal, topical, transdermal, intranasal, ocular, auricular, pulmonary or other mucosa administration. In a preferred embodiment, parenteral administration is by intramuscular injection, for example, into the subject's thigh or upper arm. The injection can be through a needle (for example, a hypodermic needle), but injection without a needle can be used alternatively. A typical intramuscular dose is 0.5 mL. The compositions of the invention can be prepared in various forms, for example, for injection as liquid solutions or suspensions. In certain embodiments, the composition can be prepared as a powder or spray for pulmonary administration, for example, in an inhaler. In other embodiments, the composition can be prepared as a suppository or pessary or for nasal administration, auricular administration, for example, as a spray, drops, gel or powder.
[0081] In one modality, intranasal administration can be used to prevent pneumonia or otitis media (as nasopharyngeal pneumococcal transport can be more effectively prevented, thereby mitigating infection in its earliest stage).
[0082] The amount of conjugate in each dose of vaccine is selected as an amount that induces an immunoprotective response without significant adverse effects. This amount may vary depending on the pneumococcal serotype. Generally, each dose will comprise from 0.1 to 100 pg of polysaccharide, particularly of
Petition 870190058765, of 6/25/2019, p. 26/64
25/46
0.1 to 10 pg, and more particularly from 1 to 5 pg.
[0083] Optimal amounts of components for a particular vaccine can be determined by standardized studies involving the observation of appropriate immune responses in subjects. After an initial vaccination, subjects may receive one or more booster immunizations that are adequately spaced.
[0084] The routine schedule for babies and young children against invasive disease caused by S. Pneumoniae due to the serotypes included in the Prev (e) nar 13 vaccine is 2, 4, 6 and 12 - 15 months of age. The compositions of the present invention are also suitable for use with older children, adolescents, and adults to whom the same or different routine schedules may apply, as determined by the qualified practitioner.
Packaging and Dosage Forms [0085] The vaccines of the invention can be packaged as a single dose or multiple doses (for example, 2 doses, 4 doses or more). For multiple dose forms, vials are typically, but not necessarily, preferred over pre-filled syringes. Suitable multiple dose formats include, but are not limited to: 2 to 10 doses per 0.1 to 2 mL container per dose. In certain embodiments, the dose is a 0.5 mL dose. See, for example, International Patent Application WO2007 / 127668, which is incorporated herein by reference.
[0086] The compositions can be presented in vials or other suitable storage containers, or they can be presented in pre-filled dispensing devices, for example, single or multi-component syringes, which can be supplied with or without needles. A syringe typically, but not necessarily, contains a single dose of the invention-containing vaccine composition of the invention, although pre-filled syringes with multiple doses are also considered. Likewise, the vial
Petition 870190058765, of 6/25/2019, p. 27/64
26/46 may include a single dose, but may alternatively include multiple doses.
[0087] Effective dosage volumes can be routinely established, but a typical dose of the composition for injection has a volume of 0.5 mL. In certain embodiments, the dose is formulated for administration to a human subject. In certain embodiments, the dose is formulated for administration to an adult human subject, adolescent, small child or baby (i.e., at most one year of age) and can, in preferred embodiments, be administered by injection.
[0088] Liquid vaccines of the invention are also suitable for reconstitution of other vaccines that are presented in lyophilized form. When the vaccine has to be used for such extemporaneous reconstitution, the invention features a kit with two or more vials, two or more syringes already filled, or one or more of each, with the contents of the syringe being used to reconstitute the contents of the vial before injection or vice versa.
[0089] Alternatively, vaccine compositions of the present invention can be lyophilized and reconstituted, for example, using one of a multitude of freeze-drying methods well known in the art to form dry, regular shaped (e.g. spherical) particles, such as micropellets or microspheres, with particle characteristics, such as medium diameter sizes, which can be selected and controlled by varying the exact methods used to prepare them. The vaccine compositions can also comprise an adjuvant, which can optionally be prepared with or be contained in dry, regularly shaped (e.g. spherical) particles, such as micropellets or microspheres. In these embodiments, the present invention also features a vaccine kit comprising a first component that includes a dry and stabilized vaccine composition, optionally also
Petition 870190058765, of 6/25/2019, p. 28/64
27/46 comprising one or more preservatives of the invention, and a second component comprising a sterile aqueous solution for reconstitution of the first component. In certain embodiments, the aqueous solution comprises one or more preservatives, and can optionally comprise at least one adjuvant (see, for example, WO2009 / 109550 (incorporated herein by reference).
[0090] In yet another modality, it selects a container in the form of multiple doses of one or more from the group consisting of, but not limited to, laboratory glassware in general, flasks, beakers, graduated cylinders, fermenters, bioreactors, tubes , tubes, bags, jars, vials, bottle caps (for example, a rubber stopper, screw cap), ampoules, syringes, double or multiple chamber syringes, syringe plugs, syringe plungers, rubber caps, plastic caps, glass caps, cartridges and disposable pens and others. The container of the present invention is not limited by the material of manufacture and includes materials such as glass, metals (for example, steel, stainless steel, aluminum and others) and polymers (for example, thermoplastics, elastomers, thermoplastic-elastomers). In a particular embodiment, the format container is a 5 mL Schott Type 1 glass bottle with a butyl stopper. Those skilled in the art will realize that the format presented above is by no means an exhaustive list, but serves only as a guide for the technician with respect to the variety of formats available for the present invention. Additional formats considered for use in the present invention can be found in published catalogs from vendors and manufacturers of laboratory equipment such as United States Plastic Corp. (Lima, OH), VWR.
Methods for Assessing Condom Effectiveness in Vaccine Compositions [0091] The present invention also introduces new methods for
Petition 870190058765, of 6/25/2019, p. 29/64
28/46 for measuring the effectiveness of a vaccine formulation comprising one or more preservative agents selected in the presence of some or all of the immunogenic and non-immunogenic components of the vaccine composition. The WHO Protocol for condom effectiveness uses USP and EP tests and includes Open Bottle Policy conditions when certain tests are performed. The typical condom effectiveness test is a unique challenge test, in which a test composition is inoculated once with a population of selected microorganisms, and the reduction in * log of the inoculated microorganism over time and under conditions Particular environmental factors (eg temperature) are compared to the log reduction of the inoculated microorganism in a control composition without the test condom (s). See, for example, Examples 2 and 3, below. However, no additional tests were required to evaluate the effectiveness of the condom with multiple contaminations, for example, to evaluate bottles and corks by inoculating the same bottles multiple times.
[0092] Therefore, the invention presents a multiple challenge test to evaluate the effectiveness of one or more condoms in an immunogenic composition, in which the test comprises at least two stages of inoculation of the test composition with a population of selected microorganisms and comparing the reduction of the inoculated microorganism (s) over time and under particular environmental conditions (for example, temperature) with the reduction in a control composition without the test condom (s). See Examples 4 and 5, below.
Condom Effectiveness [0093] Vaccine formulations containing condoms of the present invention are suitable for filling into a multiple dose vaccine vial or container compatible with, for example,
Petition 870190058765, of 6/25/2019, p. 30/64
29/46 parenteral traction, and remain stable for prolonged periods at 2-8 ° C, room temperature or 37 ° C with reduced or negligible loss of activity when compared to the same formulation without a condom (s).
[0094] The amount of condom in the formulation is selected to be a quantity that meets the safety requirements of the vaccine, as defined by the Pharmacopoeia North American (US), European or the World Health Organization (WHO), or a combination of them .
[0095] To determine condom levels according to the North American and European Pharmacopoeias (USP and EP, respectively), the vaccine formulation is inflated once with approximately 10 ⁵ to 10 ⁶ UFC / mL at time 0 (UFC = colony forming units) of:
[0096] 1. Staphilococcus aureus (Bacteria; ATCC No. 6538; SA) [0097] 2. Pseudomonas aeruginosa (Bacteria; ATCC No. 9027;
PA) [0098] 3. Candida albicans (Yeast; ATCC No. 10231; CA) [0099] 4. Aspergillus niger (Fungus; ATCC No. 16404; AN) [00100] To represent the worst reasonable case of contamination that can occur in practice during repeated use of a multiple dose presentation, WHO requires safety testing with deliberate exposure to multiple contamination events using the bacterial strains Pseudomonas aeruginosa (PA), Staphilococcus aureus (SA), Escherichia coli (EC) and Bacillus subtilis (BA). The formulations are named with 5 x 10 ³ CFU / mL of each organism at 0, 6 hours, 24 hours, 7 days and 14 days after the initial challenge and stored at 2 - 8 ° C or 22 - 24 ° C for simulate potential storage conditions in practice.
[00101] USP 29 NF 24 Supplement 2 (USP) requires that, after
Petition 870190058765, of 6/25/2019, p. 31/64
30/46 inoculation of bacterial micro-organism (s), there is a reduction of at least 1.0 log in relation to the initial calculated count (that is, at the time of inoculation) in 7 days, a reduction of at least 3.0 * log in 14 days from the previously measured value, and no increase in 28 days compared to the previously measured value. See Table 1. For yeasts and fungi, the USP requirement is that there is no increase in the time of inoculation up to 7, 14 and 28 days.
[00102] The requirements of the EP are more stringent. The requirements of EP 5 ^to Edition 5.6 (5.1.3) for parenteral and ophthalmic preparations have two components: Category A and Category B. Category A (EPA) requires, for bacteria, a reduction of at least 2.0 * log. initial calculated count at 6 hours after inoculation, a reduction of at least 3.0 * log from the previously measured value at 24 hours and no recovery at 28 days. Category B (EP-B) requires, for bacteria, a reduction of at least 1.0 log from the initial calculated count in 24 hours, a reduction of at least 3.0 log in 7 days from the previously measured value and a increase of a maximum of 0.5 log from the previously measured value (that is, no increase) in 28 days. See Table 1. For yeasts and fungi, Category A requires a reduction of at least 2.0 log in 7 days from the initial calculated count, and no increase in 28 days from the previously measured value; and Category B requires a reduction of at least 1.0 log from the initial calculated count in 14 days and no increase in 28 days from the previously measured value.
Petition 870190058765, of 6/25/2019, p. 32/64
31/46
Table 1: Acceptance Criteria for the Condom Effectiveness Test
Among the North American, European and Japanese Pharmacopoeias
Organisms Method UFC / mL reduction log 6 h 24 h 7 d 14 d 28 d Bacteria EP A * 2 3 - - NR ***EP B - 1 3 - NI **USP - - 1 3 NIJP - - - 3 NI Yeasts and Fungi EP A - - 2 - NIEP B - - - 1 NIUSP - - NI NI NIJP - - - NI NI
* Criterion A expresses the recommended effectiveness to be achieved. In justified cases, where criterion A cannot be met, criterion B must be satisfied.
** NI: No increase: It is defined as a maximum of 0.5 logw units greater than the previously measured value.
*** NR: No recovery [00103] In certain embodiments of the present invention, the preservative of the invention is effective in reducing the concentration of microorganisms in the immunogenic formulation. In certain embodiments of the invention, the vaccine formulation, comprising at least one preservative, reduces the concentration of one or more microorganisms after inoculation with said microorganisms as compared to the vaccine formulation without one or more preservatives. In a particular embodiment of the invention, the formulation shows a reduction of at least 1.0 log in the initial count of microorganisms in 24 hours, a reduction of at least 3.0 log in 7 days in relation to the previously measured value and a an increase of a maximum of 0.5 log in 28 days in relation to the previously measured value. In another particular embodiment of the invention, the formulation presents a reduction of
Petition 870190058765, of 6/25/2019, p. 33/64
32/46 at least 2.0 log of the initial calculated count in 6 hours after inoculation, a reduction of at least 3.0 log in 24 hours from the previously measured value and no recovery in 28 days, compared to the micro count - initial organisms. In another embodiment of the invention, the formulation meets the requirements of the European Pharmacopoeia (EP) for parenteral and ophthalmic preparations, in particular Category A (EP-A) and / or Category B (EP-B) of the requirements of EP 5 ^a Edition 5.6 (5.1.3). In another embodiment of the invention, the formulation meets the requirements of North American Pharmacopoeia (USP) 29 NF 24 Supplement 2 for parenteral preparations.
[00104] In certain embodiments of the invention, the at least one preservative of the invention is effective in reducing the concentration of microorganisms in a formulation when challenged with microorganisms compared to a formulation without one or more preservatives. Microorganisms can be, without limitation, one or more of the following: Pseudomonas aeruginosa, Staphilococcus aureus, Escherichia coli, Bacillus subtilis, Candida albicans Aspergillus niger and others.
[00105] In certain embodiments of the invention, microorganisms can be introduced or inoculated into the vaccine one or more times at various intervals. Inoculation can occur in the context of a deliberate experimental inoculation or in the context of a contaminated hypodermic needle entering a container of a multiple dose vaccine formulation. The interval between inoculations can be between 1 minute and 1 month. In a particular embodiment, multiple inoculations occur, after one inoculation, in 6 hours after the initial inoculation, in 24 hours after the initial inoculation, in 7 days after the initial inoculation and in 14 days after the initial inoculation.
Parameters for Vaccine and Condom Stability [00106] In certain embodiments of the present invention, antigenic
Petition 870190058765, of 6/25/2019, p. 34/64
33/46 quality of at least one antigenic determinant (i.e., polysaccharide preparation of a serotype of Streptococcus pneumoniae) in the vaccine formulation is stable over a range of storage times and temperatures. Antigenicity can be measured by methods known in the art. For example, total antigenicity can be determined using specific type antisera, as described in Example 3.
[00107] In certain embodiments of the present invention, the antigenicity of at least one antigenic determinant in the vaccine formulation is stable for at least 4 weeks, at least 6 weeks, at least 8 weeks, at least 10 weeks, at least 12 weeks, minimum 18 weeks, minimum 24 weeks, minimum 48 weeks, minimum 1 year, minimum 1.25 years, minimum 1.5 years, minimum 1.75 years, minimum 2 years, minimum 2, 25 years or at least 2.5 years. Preferably, the antigenicity of a plurality of antigenic determinants, for example, at least 50%, 75%, 80%, 85%, 90%, 95% or more of the antigenic determinants in the vaccine in a formulation are stable for at least 4 weeks, minimum 6 weeks, minimum 8 weeks, minimum 10 weeks, minimum 12 weeks, minimum 18 weeks, minimum 24 weeks, minimum 48 weeks, minimum 1 year, minimum 1.25 years, minimum minimum 1.5 years, minimum 1.75 years, minimum 2 years, minimum 2.25 years, or minimum 2.5 years.
[00108] In certain embodiments of the present invention, the antigenicity of at least one antigenic determinant in the vaccine formulation is stable when stored at about -25 ° C to about 37 ° C, or -20 to -10 ° C, or 2 to 8 ° C, or about room temperature, or 22 ° C to 28 ° C, or about 37 ° C. In a particular embodiment of the invention, antigenicity of at least one antigenic determinant in the vaccine formulation is stable after storage for at
Petition 870190058765, of 6/25/2019, p. 35/64
34/46 minimum 2.5 years at a temperature of 2 to 8 ° C.
[00109] In certain embodiments of the present invention, the concentration of the preservative of the invention is stable after storage of the vaccine at the storage durations and temperatures mentioned above. In a particular embodiment of the invention, the concentration of the condom in the vaccine formulation is stable after storage of the vaccine for at least 2.5 years at a temperature of 2 to 8 ° C. The concentration of the condom can be measured by methods known in the art. For example, Thimerosal can be measured using Cold Vapor Atomic Absorption Spectrometry (CVAAS), as described in Example 3. The concentration of 2-EP can be measured with a Reverse Phase HPLC assay, also as described in Example 3. The Reverse Phase HPLC assay can be performed as follows: The samples are swirled and diluted 1:10 in 5 mM succinate buffer in saline, centrifuged and again diluted 1:10 in 5 mM succinate buffer in saline (the final dilution of the test sample is 1: 100). The sample is then tested using the Agilent Eclipse XDB-C18 HPLC column and a linear gradient of water and acetonitrile containing trifluoroacetic acid. The quantification of the condom is then compared to a standard curve. See also Sharma et al., Biologicals 36 (1): 61 - 63 (2008).
[00110] The above statement generically describes the present invention. A more complete understanding can be obtained by reference to the following specific examples. These examples are described for illustrative purposes only and are not intended to limit the scope of the invention.
EXAMPLES
Example 1 - Preliminary condom screening kit [00111] The development of the Prev (e) nar 13 vaccine formulation
Petition 870190058765, of 6/25/2019, p. 36/64
35/46 in multiple doses started with the preliminary screening of condoms, including Phenol (0.25%), 2-Phenoxyethanol (5 mg / mL), Meta-Cresol (0.3%), Metilparaben and Propilparaben (0.18 % and 0.12%, respectively) in formulations of Prev (e) nar 13.
[00112] To test the effectiveness of the condom, vaccine aliquots were inoculated with the following organisms:
[00113] 1. Staphilococcus aureus (Bacteria; ATCC No. 6538) [00114] 2. Pseudomonas aeruginosa (Bacteria; ATCC No. 9027) [00115] 3. Candida albicans (Yeast; ATCC No. 10231) [00116] 4. Aspergillus niger (Fungus; ATCC No. 16404) [00117] Thirty milliliters (mL) of each vaccine formulation with and without Timerosal or 2-PE at the indicated concentrations or saline containing 0.02% Timerosal were inoculated in triplicate with a suspension of each test organism to achieve an inoculum density of approximately 10 ⁵ to 10 ⁶ CFU / mL at time 0 (CFU = colony forming units). The volume of each inoculum did not exceed 1% of the product volume during each deliberate challenge. The samples were mixed to ensure a uniform distribution of the challenge organisms. Another 30 mL of vaccine in triplicate (with and without a condom) was used as a negative control and named with only the culture medium to assess the inherent contamination that could be present in the sample or in the medium. Each of the three series of vaccines, and positive and negative controls, was separately incubated at 20 to 25 ^o C. The aliquots (1 mL) of the challenged samples and controls (or their appropriate ten-fold serial dilutions) were enumerated by counting duplicate plate at time 0 and at intervals of 6 hours, 24 hours, 7 days, 14 days and 28 days after inoculation.
[00118] USP 29 NF 24 Supplement 2 (USP) requires that, after inoculation of bacterial microorganism (s), there is a reduction of
Petition 870190058765, of 6/25/2019, p. 37/64
36/46 at least 1.0 log with respect to the initial calculated count (that is, at the time of inoculation) in 7 days, a reduction of at least 3.0 log in 14 days with respect to the previously measured value and no increase in 28 days from the previously measured value. See Table 1. For yeasts and fungi, the USP requirement is that there is no increase in the time of inoculation up to 7, 14 and 28 days. [00119] The requirements of the EP are more stringent. The requirements of EP 5 ^to Edition 5.6 (5.1.3) for parenteral and ophthalmic preparations have two components: Category A and Category B. Category A (EPA) requires, for bacteria, a reduction of at least 2.0 log count calculated initially at 6 hours after inoculation, a reduction of at least 3.0 log in 24 hours from the previously measured value, and no recovery at 28 days. Category B (EP-B) requires, for bacteria, a reduction of at least 1.0 log in 24 hours in relation to the initial calculated count, a reduction of at least 3.0 log in 7 days in relation to the previously measured value and an increase of a maximum of 0.5 log in 28 days in relation to the previously measured value (that is, no increase). See Table 1. For yeasts and fungi, Category A requires a reduction of at least 2.0 log in 7 days and no increase from the previously measured value in 28 days, and Category B requires a reduction of at least 1.0 log in 14 days and no increase in the previously measured value in 28 days.
[00120] Plates containing <300 CFU for bacteria or <100 CFU for yeast or fungi were used during the enumeration. For single challenge studies, the arithmetic mean count of all surviving microorganisms in triplicate and duplicate plates (6 values per moment in time) plus their diluted samples were measured and normalized to CFU / mL. The results are expressed as log10 of the average UFC / mL reduction (compared to
Petition 870190058765, of 6/25/2019, p. 38/64
37/46 with moment 0). In this case, the count of surviving microorganisms is evaluated at time 0 as the baseline and compared with the incubation times of 6 hours, 24 hours, 7 days, 14 days and 28 days.
[00121] The tested condoms showed no obvious impact on the stability of Prev (e) nar 13, except for the parabens (methylparaben and propylparaben), which showed a decrease in antigenicity linked to Prev (e) nar 13. Furthermore, phenol , meta-cresol, methyl- and propylparabens interfered with the modified Lowry protein assay (the protein concentration of the vaccine is determined by the commercially available modified lowry protein assay).
[00122] The results of the condom effectiveness test (PET) showed that all the tested condoms met the USP requirements, but not the EP criteria (EP-A or EP-B). See Table 2. 2-PE was the only candidate condom that proved to be safe at higher dosages. Consequently, additional tests of condom effectiveness were undertaken, with higher doses of 2-PE.
Petition 870190058765, of 6/25/2019, p. 39/64
38/46
Table 2: Effectiveness of potential condoms in meeting USP and EP * vaccine safety requirements after a single challenge with microorganisms
0.5 mL of condom dose Challenge Bodies Bacteria Yeast; the fungus S. aureus E. coli P. aeruginosa C. albi-cans A. niger 2-Phenoxyethanol at 5.0 mg / mLUSP Answer Answer Answer Answer Answer EP Failure Failure Failure Failure Failure 0.3% m-CresolUSP Answer Answer Answer Answer Answer EP Failure Failure Failure Answer Answer Methyl parabens at 0.18% and propyl parabens at 0.02%USP Answer Answer Answer Answer Answer EP Failure Failure Failure Answer Answer 0.25% phenolUSP Answer Answer Answer Answer Answer EP Failure Failure Failure Answer Answer
* EP-B
Example 2 - Test of condom effectiveness using the single challenge method: 2-PE and Thimerosal [00123] Thimerosal at a concentration of 0.01% is commonly used in the main licensed vaccines in the United States. The effectiveness of Timerosal as a condom was tested using the same unique challenge method described above in Example 1. The vaccine formulation Prev (e) nar 13 containing 0.01% Thimerosal (equivalent to 25 pg of mercury per dose 0.5 mL) did not meet the European acceptance criteria EP-A or EP-B established by the EP antimicrobial efficacy method. However, it went through
Petition 870190058765, of 6/25/2019, p. 40/64
39/46 acceptance limits established by North American or Japanese Pharmacopoeia, as the acceptance limits established by these compensated methods are less stringent compared to those established in the EP. See Figure 1.
[00124] 0.02% thimerosal (containing 50 pg of mercury per dose), which is equivalent to twice the recommended concentration of thimerosal in some of the vaccines licensed in the United States, or 0.04% (containing 100 pg of mercury per dose), which is equivalent to four times the recommended concentration of Thimerosal in some of the vaccines licensed in the United States, met EP acceptance criteria B, but not the strictest acceptance criteria A (with a unique micro challenge -organisms). See Figure 1.
[00125] 2-PE was more effective as a condom than Thimerosal. Although 2-PE at 2.5 mg / dose failed both acceptance criteria A and B of the EP, 2-PE at concentrations of 3.5 to 5.5 mg / dose met the acceptance criterion B of the EP. At concentrations above 6.0 mg / dose, 2-PE met both criteria for acceptance of EP-A and EP-B antimicrobial efficacy (Figure 2).
Example 3 - Unique challenge method with 2-PE and Thimerosal: Change in contaminant level [00126] The absence of condoms in the Prev (e) nar 13 vaccine formulation resulted in a slow growth of P. aeruginosa, no change in levels of C. albicans and A. niger and slow reduction of colony-forming units of S. aureus during a challenge period of 28 days at 20 - 25 ° C (Figure 3).
[00127] The presence of 0.01% Thimerosal (containing 25 pg of mercury per dose) reduced the contamination levels of all four inoculated microorganisms. However, the inhibition of S. aureus and C. albicans was weaker than the inhibition of P. aeruginosa and A. niger (Figure 4). A dose-responsive relationship was observed in the effect rate
Petition 870190058765, of 6/25/2019, p. 41/64
40/46 Timerosal antimicrobial in vaccine Prev (e) 13 formulations, particularly against C. albicans, with the reduction of contamination levels being more pronounced with 0.02% Timerosal (Figure 5). The absence of Prev (e) nar 13 in a saline formulation containing 0.02% Timerosal slightly improved the growth inhibitory efficacy of Timerosal against S. aureus and C. albicans (Figure 6). [00128] 2-PE was more effective as a condom than Thimerosal. For example, in contrast to the slow decline of S. aureus with Timerosal, the antimicrobial efficacy of 5.0 mg / dose of 2-PE resulted in the reduction of S. aureus to baseline within 24 h after inoculation (Figure 7) . Although 2-PE was less effective than Timerosal as a condom against A. niger (Figure 7), and the rate of decline in A. niger contamination was slower compared to Timerosal (Figures 4 and 5), the superior efficacy of 2-PE in relation to other strains allowed it to meet the criterion of acceptance of EP-B condom at a concentration of 3.5 and 5 mg / dose (Figure 2), whereas 0.01% Timerosal did not meet ( Figure 1).
[00129] The preservative efficacy of 2-PE at 3.5 to 5.0 mg / dose remained persistent when the formulations were stored at 37 ° C for one month or at 2 - 8 ° C for two and a half years (Figure 2). The concentration of 2-PE in a formulation was also stable (Figure 15). The immunological activity (total antigenicity) of each of the 13 serotypes present in the formulation of Prev (e) nar 13 was also stable under these storage conditions (Figure 14).
[00130] Total antigenicity was derived from both bound and unbound polysaccharides present in the vaccine for each serotype. Specific type antigenicities were determined using specific type antisera. Before the trial, the 13valent vaccine formulated with aluminum phosphate was first solubilized. The solution was then neutralized to avoid degradation induced by
Petition 870190058765, of 6/25/2019, p. 42/64
41/46 alkali. Using a nephelometer, the assay measured the rate of change in the light scattering intensity derived from the formation of the antibody-antigen complex. The antigenicities of the test samples were determined by linear regression using standard curves measured immediately before or after the analysis of the samples.
[00131] To ensure the Thimerosal content of the Prev (e) nar 13 and saline vaccine formulations, the mercury concentration was determined in some of the formulations by the method of Cold Vapor Atomic Absorption Spectrometry (CVAAS). The measured mercury concentration was very close to its predicted values, suggesting that the concentration of Timerosal in these formulations was on target and not underestimated. The measured concentration of 2-PE was also very close to its predicted value and did not change with the storage of Prev (e) nar 13 formulations with time at 2-8 ° C or 37 ° C. The concentration of 2-PE was measured with a Reverse Phase HPLC assay. The samples were swirled and diluted at 1:10 in 5 mM succinate buffer in saline, centrifuged and again diluted at 1:10 in 5 mM succinate buffer in saline. The final dilution of the test sample was 1: 100. The test used the HPLC column Agilent Eclipse XDB-C18 and a linear gradient of water and acetonitrile containing trifluoroacetic acid. 2-PE in 13vPnC multiple dose vaccine samples was quantified against a standard 2PE curve. See also Sharma et al., Biologicals 36 (1): 61 - 63 (2008).
Example 4 - Condom efficacy test using the multiple challenge method: Timerosal [00132] To assess the adequacy of the WHO Multi-dose Open Vial Policy for vaccines in multiple immunization sessions for up to a maximum of four weeks, the experimental project presented by WHO. In that study, the effectiveness of Timerosal was assessed at the concentration that is present in most
Petition 870190058765, of 6/25/2019, p. 43/64
42/46 vaccines licensed in the United States (0.01%), as well as at a higher concentration of 0.02%. To represent the worst reasonable case of contamination that can occur in practice during repeated use of a multiple dose presentation, and to test WHO requirements, vaccine formulations Prev (e) nar 13 with 0.01 or Thimerosal at 0, 02% or with 5.0 mg / dose of 2-PE were deliberately exposed to multiple contamination events using the bacterial strains recommended by the WHO, P. aeruginosa, S. aureus, E. coli and B. subtilis. The formulations were baptized with 5 x 10 ³ CFU / mL of each organism at times 0, 6 hours, 24 hours, 7 days and 14 days after the initial challenge and stored at 2 - 8 ° C or at 22 - 24 ° C for simulate potential storage conditions in practice. Saline formulation containing 0.02% Thimerosal was also used as a control to assess the potential impact of Prev (e) nar 13 on the antimicrobial efficacy of Timerosal in the formulation.
[00133] With multiple deliberate contaminations of the vaccine formulation Prev (e) nar 13 in the absence of a condom, the level of P. aeruginosa and E. coli organisms increased over the course of the study, particularly when stored at 22 - 24 ° C ( Figures 8A and 8B). The level of S. aureus in the formulation stored at 22 - 24 ° C declined slowly, similarly to that observed during the study with a single challenge (compare Figure 8A with Figure 3). The viability of B. subtilis declined even more perceptibly (Figures 8A and 8B). These results suggest that B. subtilis is not a robust organism in this formulation to be used as a model for these studies of condoms in the test of condom effectiveness, despite its recommendation by the WHO.
[00134] In the vaccine formulation Prev (e) nar 13, the antibacterial efficacy of Timerosal at 0.01% was the highest with B. subtilis, followed by P. aeruginosa. However, the reduction of S. aureus and E. coli was len
Petition 870190058765, of 6/25/2019, p. 44/64
43/46 ta, particularly when the formulations were stored at 28 ° C (Figures 9A and 9B).
[00135] As shown in the nonlinear regression analysis of the viability decay of S. aureus summarized in Figure 12, the decay rate of S. aureus was substantially slower (-5.98 log10 decay per day, with 50% decay in 30.28 days) when the formulation was stored at 2 - 8 ° C, compared to storage at 22 - 24 ° C (-1.39 logw of decay per day, with 50% decay in 6, 2 days) (Figure 12). These results show that 0.01% Thimerosal in a Prev (e) nar 13 vaccine formulation, which is contaminated in the field during a multiple dose distribution and additionally stored at a refrigerated temperature, will not be effective in reducing bacterial contamination .
[00136] The effectiveness of Timerosal was dependent on both concentration and temperature (Figures 9 and 10). Timerosal was a more effective condom at a higher concentration of 0.02%. It was also a more effective condom at a higher storage temperature of 22 - 24 ° C. However, as discussed above, even with a concentration of 0.02% and storage at 22-24 ° C, Timerosal did not meet the EP requirements of EP-A or EP-B when these criteria were applied during multiple challenge studies (Figure 1).
[00137] To study whether the vaccine itself affects the preservative action of Timerosal or not, the effectiveness of 0.02% Timerosal with multiple challenges was compared to saline and the vaccine formulation Prev (e) nar 13. In the presence of Timerosal, 0.02%, the decay rate of both S. aureus and E. coli was more pronounced in a saline formulation than in the vaccine formulation (compare Figure 11 with Figure 10 and Figure 12), demonstrating that the presence of the vaccine, to some extent, inhibited the effectiveness of Timerosal as a condom.
Petition 870190058765, of 6/25/2019, p. 45/64
44/46
However, even in a saline control formulation that did not contain the vaccine, 0.02% Timerosal still did not meet the EP-A or EP-B acceptance criteria when subjected to multiple challenges (Figure 1).
Example 5 - Condom effectiveness test using the multiple challenge method: 2-PE [00138] In contrast to the lack of effectiveness of Timerosal as a condom, particularly when inoculated multiple times or stored at 2 - 8 ° C, the formulation of Prev (e) nar 13 vaccine containing 5 mg / dose of 2-PE as the condom results in stronger inactivation of S. aureus viability, regardless of the challenge method (ie, single or multiple) or storage temperature (Figure 12).
[00139] In fact, with the multiple challenge method, regardless of storage temperature, and with all the organisms tested (P. aeruginosa, S. aureus, E. coli and B. subtilis), 2-PE at 5 mg / dose of was superior as a condom to 0.01% Timerosal. In a nonlinear regression analysis of S. aureus decay in several challenge studies, vaccine formulations with 2-PE had a faster rate of decay of microbial coatings than those with Timerosal, both in terms of 50% of decay, as well as the mean decay slope (log10 of decay / day). See Figure 12. In addition, 2-PE at 5 mg / dose met the EP-B criterion under multiple challenges, whereas no version of Timerosal was able to do so under the same conditions (Figure 13).
[00140] Thimerosal is not an effective condom in protecting Prev (e) nar 13 in the formulation of multiple doses against potential contamination that can be introduced during distribution. This is even more evident when contamination is introduced multiple times.
Petition 870190058765, of 6/25/2019, p. 46/64
45/46 times when dosing subjects in multiple dose formulations. Thimerosal has a slow rate of inactivation, particularly against S. aureus and E. coli, with a delay in the immediate effect of cleaning potential contaminating organisms when general practitioners could remove vaccines from multiple dose vials under unhygienic conditions. However, 2-PE from 3.5 to 5 mg / dose is stable, with a much higher rate of antimicrobial efficacy compared to Timerosal and, consequently, will protect the product against inadvertent contamination when dosing subjects.
Example 6 - Immune response elicited by immunization with Prevenar 13 with or without 2-phenoxy ethanol as a preservative in non-human primates [00141] The ability of Prevenar 13 and Prevenar 13 containing 2 phenoxy ethanol to induce an immune response is evaluated in cynomolgus monkeys.
[00142] Two immunization groups of 10 monkeys for a total of 20 cynomolgus monkeys are used for the study, as detailed in Table 3.
Table 3
Group Monkeys / group Vaccine Final Volume Distribution 1 10 13vPnC 0.5 mL IM 2 10 13vPnC + 5 mg 2PE 0.5 mL IM
[00143] Pre-screened animals are randomized into groups based on their body weights and baseline titers.
[00144] Monkeys receive a clinical dose of 13vPnC containing 0 or 5 mg of 2-phenoxyethanol as a condom. The vaccine is given intramuscularly at a single site in the quadriceps muscle of each monkey. The final volume distributed is 0.5 ml.
[00145] All monkeys receive three doses and are vaccinated at weeks 2, 4 and 8.
Petition 870190058765, of 6/25/2019, p. 47/64
46/46 [00146] Blood extraction schedule: Peripheral blood is sampled at weeks 0, 6, 8, 10, 12 and 16 to monitor the induction of immune responses to vaccines.
[00147] The immune response caused by vaccination is monitored by performing the following tests with serum collected during the study: [00148] · In vitro binding and functional antibodies:
[00149] - ELISA-specific serotype IgG (see, for example, Fernsten P, et al., Hum Vaccin. 2011 Jan 1; 7: 75-84) [00150] - Serotype-specific opsonophagocytosis assay (OPA) ( see, for example, Fernsten P, et al., Hum Vaccin. 2011 Jan 1; 7: 75-84) [00151] · In vivo protection in the baby rat challenge model (see, for example, Fernsten P, et al ., Hum Vaccin. 2011 Jan 1; 7: 75-84): [00152] - Serums from assembled monkeys are assessed for specific serotype protection.

权利要求:
Claims (19)
[1]
1. Multivalent immunogenic composition, characterized by the fact that it comprises polysaccharide-protein conjugates consisting of capsular polysaccharides of Streptococcus pneumoniae of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, individually conjugated to CRM197, and further comprising 2-phenoxyethanol (2-PE) at a concentration between 7 mg / ml and 15 mg / ml.
[2]
2. Multivalent immunogenic composition according to claim 1, characterized by the fact that said composition comprises 2-PE at a concentration of 10 mg / mL.
[3]
3. Multivalent immunogenic composition, according to claim 1, characterized by the fact that said composition comprises 2-PE at a concentration of 4.0 mg / dose, the dose being a dose of 0.5 ml.
[4]
Multivalent immunogenic composition according to any one of claims 1 to 3, characterized in that said composition further comprises an adjuvant, and said adjuvant is aluminum phosphate.
[5]
5. Multivalent immunogenic composition according to any one of claims 1 to 4, characterized by the fact that the antigenicity of the immunogenic composition is stable for at least 1 year, 1.5 years, 2 years or 2.5 years.
[6]
6. Multivalent immunogenic composition according to any one of claims 1 to 5, characterized by the fact that, after inoculation with one or more microorganisms, the concentration of said microorganisms is reduced over time.
[7]
7. Multivalent immunogenic composition, according to claim 6, characterized by the fact that the strains of microorganisms are one or more strains selected from P. aerugino-
Petition 870190058765, of 6/25/2019, p. 49/64
2/3 sa, S. aureus, E. coli and B. subtilis.
[8]
8. Multivalent immunogenic composition according to claim 6 or 7, characterized by the fact that the composition is inoculated multiple times.
[9]
9. Multivalent immunogenic composition according to claim 7 or 8, characterized by the fact that a second inoculation occurs 6 hours after the initial inoculation, a third inoculation occurs 24 hours after the initial inoculation, a third inoculation occurs 7 days after initial inoculation and a fourth inoculation occurs 14 days after the initial inoculation.
[10]
10. Multivalent immunogenic composition according to any one of claims 1 to 9, characterized in that said composition further comprises one or more of a buffer, a cryoprotectant, a salt, a divalent cation, a non-ionic detergent and a inhibitor of oxidation of free radicals.
[11]
11. Formulation, characterized by the fact that it is of multivalent immunogenic composition of pneumococcal capsular polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, individually conjugated to CRM197 , and the multivalent immunogenic composition is formulated in a sterile liquid to understand:
4.4 pg / mL of each polysaccharide, except for 6B to 8.8 pg / mL;
58 pg / ml of CRM197 vehicle protein;
0.25 mg / mL of elemental aluminum in the form of aluminum phosphate;
0.85% sodium chloride;
0.02% polysorbate 80;
5 mM sodium succinate buffer at a pH of 5.8; and
10 mg / ml of 2-phenoxyethanol.
Petition 870190058765, of 6/25/2019, p. 50/64
3/3
[12]
12. Vial, characterized by the fact that it contains a multivalent immunogenic composition, as defined in any one of claims 1 to 11.
[13]
13. Flask according to claim 12, characterized in that said flask contains more than one dose of the immunogenic composition.
[14]
14. Pre-filled vaccine delivery device, characterized by the fact that it comprises a multivalent immunogenic composition as defined in any one of claims 1 to
11.
[15]
15. Pre-filled vaccine delivery device according to claim 14, characterized in that said device is or comprises a syringe.
[16]
16. Kit for the preparation of the multivalent immunogenic composition, as defined in any one of claims 1 to 11, characterized in that it comprises (i) said plurality of capsular polysaccharides in a lyophilized form of the composition, as defined in any of the claims 1 to 11, and (ii) aqueous material to reconstitute component (i) to provide the aqueous composition.
[17]
17. Container, characterized by the fact that it comprises two doses or more, at 0.1 to 2 ml per dose, of the multivalent immunogenic composition, as defined in any one of claims 1 to 11.
[18]
18. Container according to claim 17, characterized by the fact that the dose is a 0.5 ml dose.
[19]
19. Container according to claim 17 or 18, characterized in that it comprises from 2 to 10 doses.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP5959161B2|2016-08-02|Vaccine preparation

---

JP6321094B2|2018-05-09|New formulations that stabilize immunogenic compositions and inhibit precipitation

---

US20190330265A1|2019-10-31|Glycoconjugation process

---

CA2646993C|2016-01-26|Regimens for immunisation with meningococcal conjugates

---

ES2614815T3|2017-06-02|Stable immunogenic compositions of Staphylococcus aureus antigens

---

CA2819366A1|2012-06-14|Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions

---

JP2009535353A5|2014-09-04|

---

US20150320852A1|2015-11-12|Conjugates for protecting against diphtheria and/or tetanus

---

WO2019220304A1|2019-11-21|15 valent pneumococcal polysaccharide conjugate vaccine

---

BR122020000550B1|2021-12-07|IMMUNOGENIC COMPOSITION COMPRISING PN-SOROTYPE 12F CONJUGUATED WITH A CARRIER PROTEIN AND ITS USE

同族专利:

---

公开号 | 公开日

---

PT3170508T|2020-01-16|

---

RU2607024C2|2017-01-10|

---

US20130072881A1|2013-03-21|

---

WO2011151760A3|2012-03-01|

---

HUE048398T2|2020-07-28|

---

CA2799747C|2016-10-18|

---

DK3170508T3|2020-01-02|

---

BR112012030950A2|2016-11-01|

---

US9095567B2|2015-08-04|

---

ES2764674T3|2020-06-04|

---

EP3626263A1|2020-03-25|

---

EP2575870A2|2013-04-10|

---

MX2012013664A|2013-01-24|

---

IL223206A|2017-04-30|

---

RU2012151376A|2014-07-20|

---

PL2575870T3|2017-05-31|

---

KR101609032B1|2016-04-04|

---

WO2011151760A2|2011-12-08|

---

SI2575870T1|2017-01-31|

---

EP3170508A1|2017-05-24|

---

JP2011256168A|2011-12-22|

---

PT2575870T|2017-02-10|

---

SI3170508T1|2020-01-31|

---

ES2614807T3|2017-06-02|

---

IL223206D0|2013-02-03|

---

PL3170508T3|2020-04-30|

---

CA2799747A1|2011-12-08|

---

JP5959161B2|2016-08-02|

---

AU2011262346A1|2012-12-06|

---

CN102933229A|2013-02-13|

---

AU2011262346B2|2014-12-11|

---

CN107080838A|2017-08-22|

---

HUE033071T2|2017-11-28|

---

JP2015143252A|2015-08-06|

---

EP3170508B1|2019-11-13|

---

EP2575870B1|2016-12-07|

---

KR20130041064A|2013-04-24|

---

DK2575870T3|2017-02-13|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4673574A|1981-08-31|1987-06-16|Anderson Porter W|Immunogenic conjugates|

---

US4902506A|1983-07-05|1990-02-20|The University Of Rochester|Immunogenic conjugates|

---

SE8405493D0|1984-11-01|1984-11-01|Bror Morein|IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS|

---

US5078996A|1985-08-16|1992-01-07|Immunex Corporation|Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor|

---

US5057540A|1987-05-29|1991-10-15|Cambridge Biotech Corporation|Saponin adjuvant|

---

FR2630115B1|1988-04-14|1994-10-28|Merieux Inst|PROCESS FOR STABILIZING HUMAN ALBUMIN SOLUTIONS AND SOLUTION OBTAINED|

---

US4912094B1|1988-06-29|1994-02-15|Ribi Immunochem Research Inc.|Modified lipopolysaccharides and process of preparation|

---

WO1990014837A1|1989-05-25|1990-12-13|Chiron Corporation|Adjuvant formulation comprising a submicron oil droplet emulsion|

---

ES2082052T3|1990-07-19|1996-03-16|Nardino Righi|SAFETY SYRINGE, SINGLE USE.|

---

IL101715A|1991-05-02|2005-06-19|Amgen Inc|Recombinant dna-derived cholera toxin subunit analogs|

---

US5769047A|1991-12-23|1998-06-23|Zoche; Michael|Engine with oil separator|

---

IT1253009B|1991-12-31|1995-07-10|Sclavo Ricerca S R L|DETOXIFIED IMMUNOGENIC MUTANTS OF COLERIC TOXIN AND TOXIN LT, THEIR PREPARATION AND USE FOR THE PREPARATION OF VACCINES|

---

CA2138997C|1992-06-25|2003-06-03|Jean-Paul Prieels|Vaccine composition containing adjuvants|

---

DE69434079T2|1993-03-05|2005-02-24|Wyeth Holdings Corp.|Plasmid for the production of CRM protein and diphtheria toxin|

---

GB9326253D0|1993-12-23|1994-02-23|Smithkline Beecham Biolog|Vaccines|

---

JP3696267B2|1994-02-28|2005-09-14|天野エンザイム株式会社|Method for stabilizing bioactive protein|

---

US5571515A|1994-04-18|1996-11-05|The Wistar Institute Of Anatomy & Biology|Compositions and methods for use of IL-12 as an adjuvant|

---

US6207646B1|1994-07-15|2001-03-27|University Of Iowa Research Foundation|Immunostimulatory nucleic acid molecules|

---

DE69637254T2|1995-04-25|2008-06-19|Glaxosmithkline Biologicals S.A.|Vaccines containing a saponin and a sterol|

---

RU2087156C1|1995-06-22|1997-08-20|Леонид Николаевич Падюков|Vaccine for pneumococcal infection control|

---

US5846547A|1996-01-22|1998-12-08|Regents Of The University Of Minnesota|Streptococcal C5a peptidase vaccine|

---

RU2098109C1|1996-09-26|1997-12-10|Александр Григорьевич Чучалин|Antiallergic, antiinflammatory agent, method of its preparing, curative and cosmetic agent and its use|

---

JP4078406B2|1997-01-22|2008-04-23|有限会社コーキ・エンジニアリング|Method for manufacturing syringe cylinder|

---

US6113918A|1997-05-08|2000-09-05|Ribi Immunochem Research, Inc.|Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors|

---

US6224880B1|1997-09-24|2001-05-01|Merck & Co., Inc.|Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines|

---

CA2264970A1|1998-03-10|1999-09-10|American Cyanamid Company|Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria|

---

DK1117435T3|1998-09-30|2008-03-17|Wyeth Corp|Mutated cholera-holotoxin as adjuvant|

---

US6355255B1|1998-12-07|2002-03-12|Regents Of The University Of Minnesota|Streptococcal C5a peptidase vaccine|

---

KR100642044B1|1999-03-19|2006-11-10|글락소스미스클라인 바이오로지칼즈 에스.에이.|Vaccine|

---

GB9909077D0|1999-04-20|1999-06-16|Smithkline Beecham Biolog|Novel compositions|

---

EP1233784B1|1999-12-02|2008-07-09|Novartis Vaccines and Diagnostics, Inc.|Compositions and methods for stabilizing biological molecules upon lyophilization|

---

DE10012370A1|2000-03-14|2001-09-27|Chiron Behring Gmbh & Co|Use of oil-in-water emulsion as vaccine adjuvant, particularly for influenza and pneumococcal vaccines, administered at different site from the vaccine|

---

RU2293573C2|2000-06-08|2007-02-20|Интерселл Аг|Immunostimulating oligodeoxynucleotides|

---

NZ523319A|2000-06-29|2006-01-27|Glaxosmithkline Biolog Sa|Vaccine compositions comprising Pw, TT, DT and H. influenzae type B with a lower dose of Hib compared with the standard does |

---

KR100385711B1|2000-07-05|2003-05-27|녹십자백신 주식회사|The quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis b surface antigen and the preparation thereof|

---

AT410635B|2000-10-18|2003-06-25|Cistem Biotechnologies Gmbh|VACCINE COMPOSITION|

---

GB0108364D0|2001-04-03|2001-05-23|Glaxosmithkline Biolog Sa|Vaccine composition|

---

AU2002346249B2|2001-06-07|2007-03-15|The Regents Of The University Of Colorado|Mutant Forms of Cholera Holotoxin as an Adjuvant|

---

MXPA03011135A|2001-06-07|2004-09-08|Wyeth Corp|Mutant forms of cholera holotoxin as an adjuvant.|

---

MX339524B|2001-10-11|2016-05-30|Wyeth Corp|Novel immunogenic compositions for the prevention and treatment of meningococcal disease.|

---

PT1441589E|2001-11-08|2012-08-13|Abbott Biotherapeutics Corp|Stable liquid pharmaceutical formulation of igg antibodies|

---

CA2512917A1|2003-01-15|2004-08-05|Wyeth Holdings Corporation|Methods for increasing neisseria protein expression|

---

PT2172213E|2003-01-30|2013-06-03|Novartis Ag|Injectable vaccines against multiple meningococcal serogroups|

---

MY162623A|2003-02-10|2017-06-30|Biogen Ma Inc|Immunoglobulin formulation and method of preparation thereof|

---

CA2519511A1|2003-03-17|2004-09-30|Wyeth Holdings Corporation|Mutant cholera holotoxin as an adjuvant and an antigen carrier protein|

---

BRPI0409459A|2003-04-16|2006-05-02|Wyeth Corp|New Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease|

---

TW200509930A|2003-06-25|2005-03-16|Elan Pharm Inc|Methods and compositions for treating rheumatoid arthritis|

---

UA67144A|2003-07-29|2004-06-15|Inst Exprm & Clinical Veterina|Method for production of inactivated vaccine against salmonellosis and escherichiosis of animals|

---

DE10348550A1|2003-10-20|2005-06-16|Hexal Biotech Forschungsgmbh|Stable aqueous G-CSF-containing compositions|

---

RU37462U1|2004-01-16|2004-04-27|Бычкова Ольга Владимировна|TEST|

---

CA2595380A1|2005-01-28|2006-08-03|Wyeth|Stabilized liquid polypeptide formulations|

---

US20070184072A1|2005-04-08|2007-08-09|Wyeth|Multivalent pneumococcal polysaccharide-protein conjugate composition|

---

US7955605B2|2005-04-08|2011-06-07|Wyeth Llc|Multivalent pneumococcal polysaccharide-protein conjugate composition|

---

US7709001B2|2005-04-08|2010-05-04|Wyeth Llc|Multivalent pneumococcal polysaccharide-protein conjugate composition|

---

JP4472770B2|2005-04-08|2010-06-02|ワイスエルエルシー|Polyvalent pneumococcal polysaccharide-protein conjugate composition|

---

EP2308505A3|2005-09-01|2011-11-30|Novartis Vaccines and Diagnostics GmbH|Multiple vaccines including serogroup C meningococcus|

---

KR100659373B1|2006-02-09|2006-12-19|서울옵토디바이스주식회사|Patterned substrate for light emitting diode and light emitting diode employing the same|

---

KR101838938B1|2006-03-17|2018-03-15|더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브헬스 앤드 휴먼 서비시즈|Methods for preparing complex multivalent immunogenic conjugates|

---

TW200806315A|2006-04-26|2008-02-01|Wyeth Corp|Novel formulations which stabilize and inhibit precipitation of immunogenic compositions|

---

US20070253985A1|2006-04-26|2007-11-01|Wyeth|Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations|

---

US8808707B1|2006-05-08|2014-08-19|Wyeth Llc|Pneumococcal dosing regimen|

---

EP2589392B1|2008-03-05|2016-11-30|Sanofi Pasteur|Process for stabilizing an adjuvant containing vaccine composition|

---

DE102009056871A1|2009-12-03|2011-06-22|Novartis AG, 4056|Vaccine adjuvants and improved methods of making the same|

---

WO2011141819A1|2010-05-12|2011-11-17|Novartis Ag|Improved methods for preparing squalene|

---

PT2575870T|2010-06-04|2017-02-10|Wyeth Llc|Vaccine formulations|

---

EP2648506A1|2010-12-10|2013-10-16|Merck Sharp & Dohme Corp.|Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions|

---

KR101808398B1|2010-12-22|2017-12-12|와이어쓰 엘엘씨|Stable immunogenic compositions of staphylococcus aureus antigens|

---

ES2596194T3|2011-04-01|2017-01-05|Wyeth Llc|Antibody-drug conjugates|

---

KR20150020164A|2012-05-15|2015-02-25|수브하시 브이. 카프레|Adjuvant formulations and methods|PT2575870T|2010-06-04|2017-02-10|Wyeth Llc|Vaccine formulations|

---

US9186295B2|2011-10-25|2015-11-17|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

KR20150020164A|2012-05-15|2015-02-25|수브하시 브이. 카프레|Adjuvant formulations and methods|

---

KR102057217B1|2012-06-20|2020-01-22|에스케이바이오사이언스 주식회사|Multivalent pneumococcal polysaccharide-protein conjugate composition|

---

KR20140075196A|2012-12-11|2014-06-19|에스케이케미칼주식회사|Multivalent pneumococcal polysaccharide-protein conjugate composition|

---

US9707153B2|2013-04-24|2017-07-18|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

US9849066B2|2013-04-24|2017-12-26|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

US9700485B2|2013-04-24|2017-07-11|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

US9707155B2|2013-04-24|2017-07-18|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

US9713572B2|2013-04-24|2017-07-25|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

US9603775B2|2013-04-24|2017-03-28|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

US9700486B2|2013-04-24|2017-07-11|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

US9707154B2|2013-04-24|2017-07-18|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

US9717648B2|2013-04-24|2017-08-01|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

US9717649B2|2013-04-24|2017-08-01|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

US9839579B2|2013-04-24|2017-12-12|Corning Incorporated|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|

---

WO2014186754A2|2013-05-16|2014-11-20|Board Of Regents The University Of Texas System|Dry solid aluminum adjuvant-containing vaccines and related methods thereof|

---

US11160855B2|2014-01-21|2021-11-02|Pfizer Inc.|Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof|

---

CN103893751B|2014-03-26|2016-04-20|天津康希诺生物技术有限公司|A kind of pneumococal polysaccharide Protein Conjugation vaccine and preparation method thereof|

---

US20180296661A1|2015-06-09|2018-10-18|The Board Of Regents Of The University Of Oklahoma|Compositions and Treatments for Haemophilus Influenzae|

---

EP3344276B1|2015-09-03|2020-04-22|The Board of Regents of the University of Oklahoma|Peptide inhibitors of clostridium difficile tcdb toxin|

---

CN105233296B|2015-11-24|2018-08-17|江苏省农业科学院|Heat-resisting lyophilized protecting agent and its preparation method and application for duck virus hepatitis live vaccine|

---

AU2017248674B2|2016-04-14|2021-04-01|Boehringer Ingelheim Animal Health USA Inc.|Multi-dose compositions containing an antimicrobial polyamide or octenidine preservative|

---

MA45283B1|2016-09-06|2021-05-31|Lg Chemical Ltd|A COMPOSITION OF MULTIVALENT PNEUMOCOCCAL POLYSACCARID-CAPSULAR CARRIER PROTEIN COMBINES AND USE FROM THIS|

---

CN106822884B|2016-12-28|2021-04-30|北京民海生物科技有限公司|Preparation method of multivalent pneumococcal capsular polysaccharide conjugate vaccine|

---

WO2018144439A1|2017-01-31|2018-08-09|Merck Sharp & Dohme Corp.|Methods for making polysaccharide-protein conjugates|

---

AU2018225099A1|2017-02-24|2019-07-25|Merck Sharp & Dohme Corp.|Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates|

---

WO2018169303A1|2017-03-15|2018-09-20|주식회사 엘지화학|Polyvalent streptococcus pneumoniae vaccine composition|

---

US10729763B2|2017-06-10|2020-08-04|Inventprise, Llc|Mixtures of polysaccharide-protein pegylated compounds|

---

CN111132691A|2017-06-10|2020-05-08|创赏有限公司|Multivalent conjugate vaccines with divalent or multivalent conjugate polysaccharides providing improved immunogenicity and avidity|

---

KR20200096266A|2017-12-06|2020-08-11|머크 샤프 앤드 돔 코포레이션|Composition comprising Streptococcus pneumoniae polysaccharide-protein conjugate and method of using the same|

---

EP3782642A1|2018-04-18|2021-02-24|SK Bioscience Co., Ltd.|Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof|

---

WO2020021416A1|2018-07-21|2020-01-30|Biological E Limited|Vaccine formulations comprising preservative system|

---

CN113293115A|2021-07-08|2021-08-24|成都生物制品研究所有限责任公司|Streptococcus pneumoniae non-animal source freeze-drying protective agent|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-01-29| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-06-11| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|

---

2019-12-03| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-02-04| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2011, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US35180410P| true| 2010-06-04|2010-06-04|

---

PCT/IB2011/052275|WO2011151760A2|2010-06-04|2011-05-25|Vaccine formulations|

---